Title: Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity.
Journal: Bioorganic & medicinal chemistry letters 20090401
Title: 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis.
Journal: Molecular pharmacology 20090301
Title: Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Journal: Nature chemical biology 20090201
Title: Optimization of halopemide for phospholipase D2 inhibition.
Journal: Bioorganic & medicinal chemistry letters 20070415
Title: Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment.
Journal: European archives of psychiatry and clinical neuroscience 20041001
Title: Scott SA, et al. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness. Nat Chem Biol. 2009 Feb;5(2):108-17.
Title: Neale R, et al. Acute dyskinesias in monkeys elicited by halopemide, mezilamine and the "antidyskinetic" drugs, oxiperomide and tiapride. Psychopharmacology (Berl). 1981;75(3):254-7.
Title: Skafi N, et al. Phospholipase D: A new mediator during high phosphate-induced vascular calcification associated with chronic kidney disease. J Cell Physiol. 2019 Apr;234(4):4825-4839.
